All 1 tracked stories fall under one category: pharma. Acorn Energy, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. CorMedix Inc. appears in 1 tracked Biotech story from March 6, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about CorMedix Inc.
All 1 tracked stories fall under one category: pharma. Acorn Energy, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. CorMedix Inc. appears in 1 tracked Biotech story from March 6, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering CorMedix Inc.. Shared-story counts are live from our verified record — not editorial picks.
CorMedix Inc. (NASDAQ: CRMD) reported its Q4 2025 financial results, highlighting the successful commercial ramp-up of DefenCath, the first FDA-approved antimicrobial catheter lock solution. The company is focusing on securing major dialysis organization contracts and optimizing reimbursement pathways to solidify its market position.
CorMedix Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.